Trial Profile
Phase 1, Open Label, Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs YS ON 001 (Primary)
- Indications Advanced breast cancer; Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Yisheng Biopharma; YS Biopharma
- 04 Dec 2023 Status changed from recruiting to completed.
- 14 Mar 2023 According to a YS Biopharma media release, the Yisheng Biopharma merged with Summit Healthcare Acquisition Corp and the combine company is named as YS Biopharma.
- 20 Dec 2022 Planned End Date changed from 1 Dec 2019 to 1 Dec 2023.